Comerica Bank
PHAT icon

Comerica Bank’s Phathom Pharmaceuticals PHAT Stock Holding History

Comerica Bank’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-129
Closed -$1.33K – 3747
2024
Q2 		$1.33K Buy
+129
New +$1.33K ﹤0.01% 3557

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Comerica Bank's PHAT Position: Q3 2024 in Review

Comerica Bank sold out of Phathom Pharmaceuticals (PHAT) in Q3 2024, closing a stake of 129 shares — an estimated $1.33K sold.

Comerica Bank first reported a position in PHAT in Q2 2024 and held it in 1 quarter. The position peaked at $1.33K in Q2 2024. 133 funds tracked by Wall St. Rank hold PHAT as of Q3 2024.

  • Comerica Bank reported no remaining Phathom Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Comerica Bank sold 129 Phathom Pharmaceuticals shares in Q3 2024, an estimated $1.33K.
  • Comerica Bank first reported a position in Phathom Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Comerica Bank's Phathom Pharmaceuticals position peaked at $1.33K in Q2 2024.
  • 133 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2024.

Based on Comerica Bank's 13F filing for Q3 2024, filed 14 Nov 2024.